• Earlier this month, Herbalife reported quarterly revenues of US$1.33 billion, up 5.4% year on year and 1.5% above analyst expectations, but significantly missed earnings-per-share estimates and issued relatively weak forward guidance.
• This combination of stronger sales but softer profitability and outlook highlights an ongoing tension between Herbalife’s top-line momentum and its ability to convert that into earnings growth.
• We’ll now examine how Herbalife’s revenue beat but weak guidance update may reshape its existing investment narrative and risk profile.

The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Herbalife Investment Narrative Recap

To own Herbalife today, you need to believe the company can translate modest revenue growth and its wellness repositioning into healthier, more consistent earnings despite a stressed balance sheet. The latest quarter’s revenue beat but EPS miss and softer guidance put the short term spotlight on margin pressure and execution, while the biggest immediate risk remains its thin profitability combined with negative equity and interest costs that are not well covered by earnings.

The most relevant recent development here is Herbalife’s 2026 refinancing package, which extends debt maturities and reshapes its credit facilities. In the context of a quarter where net income turned into a loss and guidance weakened, that refinancing looks more like essential breathing room than a growth lever, and it matters directly for the key catalyst of improved cash flow and for the risk that high leverage could limit Herbalife’s options if earnings stay under pressure.

Yet behind the revenue beat, investors should be aware of how Herbalife’s high leverage and negative equity could quickly magnify any further earnings disappointment...

Herbalife's narrative projects $5.6 billion revenue and $506.4 million earnings by 2029.

Uncover how Herbalife's forecasts yield a $17.00 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Some of the lowest rated analysts were already cautious, assuming revenue of about US$5.5 billion and earnings near US$296.7 million by 2029, so this mixed quarter and weaker guidance may push their already more pessimistic view on distributor pressure and debt risks even further, highlighting just how differently you and other investors might interpret the same numbers.

Explore 5 other fair value estimates on Herbalife - why the stock might be worth just $17.00!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Herbalife research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Herbalife research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Herbalife's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.